Intracellular protein-protein interactions (PPIs) have long been considered "undruggable" targets. Stapled peptides, with their stabilized alpha-helical structure, cell penetration capability, and resistance to proteolysis, are changing this paradigm. This guide explores stapled peptide technology, design principles, and therapeutic applications.
The Challenge of Intracellular PPIs
Why PPIs Are Difficult Targets
Protein-protein interactions typically feature:
Large, flat binding surfaces (500-3000 square angstroms)No deep pockets for small molecule bindingDistributed binding energy across many residuesOften intracellular locationTraditional Approaches and Limitations
**Small Molecules:**
Excellent cell penetrationCannot effectively cover large PPI surfacesFew successful examples (nutlins being notable exception)**Antibodies:**
High specificity for protein targetsCannot access intracellular spaceLimited to extracellular targets**Linear Peptides:**
Can cover PPI surfacesPoor cell penetrationRapid proteolytic degradationFlexible, loses binding conformationStapled Peptide Technology
The Concept
Stapling involves covalently linking amino acid side chains across one face of an alpha-helix, typically using hydrocarbon tethers. This:
Stabilizes the helical conformationProtects the backbone from proteasesCovers hydrophobic surface area, improving cell penetrationMaintains or enhances binding affinityTypes of Staples
**All-Hydrocarbon Staples:**
Olefin metathesis between alpha-methylated residuesi, i+4 staple spans one helical turni, i+7 staple spans two turnsMost extensively characterized**Lactam Staples:**
Lys-Asp or Lys-Glu linkagesAmide bond formationShorter staples**Triazole Staples:**
Click chemistry approachAzide-alkyne cycloadditionBioorthogonal installation possible**Disulfide Staples:**
Cys-Cys basedReversible in reducing environmentsSimpler chemistry but less stableDouble and Stitched Staples
Multiple staples along the helix"Stitched" peptides with continuous backbone linkageFurther enhanced stability and helicityDesign Principles
Identifying Staple-Compatible Sequences
Starting requirements:
Target interaction mediated by alpha-helixCrystal structure or homology model availableKey binding residues identifiedResidues available for staple placementStaple Positioning Rules
**Critical Considerations:**
Staple must be on non-binding face of helixAvoid disrupting key binding residuesConsider helix registry (which face to staple)i, i+4 for shorter peptides; i, i+7 for longer**Scanning Approach:**
Systematically move staple positionEvaluate helicity, binding, cell penetrationOptimize iterativelySequence Optimization
Beyond stapling:
N-methylation can improve propertiesD-amino acid substitutions (non-critical positions)Charge modifications for solubilityN- and C-terminal modificationsProperties and Characterization
Helicity Assessment
**Circular Dichroism (CD):**
Characteristic minima at 208 and 222 nmQuantify percent helicityCompare to linear control**NMR:**
NOE patterns confirm helical structureDetailed structural informationSolution behaviorProteolytic Stability
Incubate with serum or specific proteasesHPLC or mass spec monitoringCompare to linear peptide half-lifeTypically 10-100 fold improvementCell Penetration
**Methods:**
Fluorescently labeled peptideFlow cytometry for quantificationConfocal microscopy for localizationSubcellular fractionation**Factors Affecting Uptake:**
Staple composition and positionOverall chargeHydrophobicityCell typeTarget Engagement
Intracellular binding assaysCo-immunoprecipitationProximity ligation assaysCellular thermal shift assay (CETSA)Key Targets and Programs
p53-MDM2/MDMX Interaction
Most advanced stapled peptide targetALRN-6924: Clinical candidateReactivates p53 tumor suppressorDual MDM2/MDMX inhibitionBCL-2 Family
BH3 domain mimeticsPro-apoptotic activity in cancerBIM, BAD stapled peptidesMCL-1 targetingBeta-Catenin/TCF
Wnt pathway inhibitionCancer applicationsStAx peptidesEstrogen Receptor
Coactivator interaction disruptionBreast cancer applicationsNotch Pathway
MAML coactivator disruptionCancer applicationsRAS
Direct targeting attemptsChallenging but high value targetSynthesis and Production
Staple Installation
**Olefin Metathesis:**
Specialized alpha-methyl amino acidsGrubbs catalyst (typically 2nd generation)Can be performed on-resin or in solution**Synthetic Challenges:**
Non-natural amino acid incorporationMetathesis efficiency varies by sequenceProtecting group compatibilityScale-up considerationsQuality Considerations
Confirm staple formation (mass spec)Assess stereochemistryMeasure helicityVerify target bindingTherapeutic Development Challenges
Delivery
Oral bioavailability remains challengingCurrent clinical candidates are injectableFormulation optimization ongoingManufacturing
Complex synthesisSpecialized starting materialsCost of goods considerationsOff-Target Effects
Cell penetration may cause non-specific effectsThorough selectivity profiling neededToxicology studies essentialCurrent Clinical Status
ALRN-6924 (Aileron)
Most advanced clinical candidatep53-MDM2/MDMX dual inhibitorMultiple Phase 1/2 trialsCombination studies with chemotherapyOther Programs
Several preclinical candidatesVarious targets and indicationsAcademic and industry programsFuture Directions
Technology Improvements
Better prediction of cell penetrationStaple chemistry optimizationOral delivery strategiesTargeting specific tissuesTarget Expansion
More intracellular PPIsTranscription factor complexesSignal transduction nodesPreviously "undruggable" targetsCombination Strategies
Checkpoint inhibitor combinationsChemotherapy combinationsTargeted therapy combinationsConclusion
Stapled peptides represent a genuine platform technology for targeting intracellular PPIs. By solving the cell penetration and stability problems that plagued linear peptides, stapling has opened new therapeutic possibilities. While challenges remain in oral delivery and manufacturing, the clinical progress of ALRN-6924 and others validates the approach. For researchers studying intracellular protein interactions, stapled peptides offer unique tools and therapeutic opportunities.